Friday, November 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Novo Nordisk CEO defends diversification strategy

Novo Nordisk CEO defends diversification strategy

in News
Novo Nordisk strikes deal with Hims & Hers to sell Wegovy and Ozempic
Share on LinkedinShare on WhatsApp

Speaking to reporters Tuesday after the company’s stock fell nearly 8%, Novo CEO Mike Doustdar defended his diversification strategy as the company mulls M&A opportunities amid increasing competition. 

“Let’s see where the gaps are, and let’s go out and see who has produced or is about to introduce better drugs than we are able to do on our own, and when that gap can be filled with M&A, we are actually quite interested about it.”

“I think yesterday we laid out a more clear strategy of the direction we want to take the company at. We talked about diversification of the company, but yet the reaction tells me that there’s still some work to do in convincing some of the investors,” Doustdar said. 

Doustdar stated that the company intends to diversify beyond its primary focus on diabetes and obesity. This includes expanding its portfolio to encompass blood and endocrine disorders, liver diseases, and cardiovascular diseases. 

“It is the right time now that I feel comfortable about the core to speak about the diversification of the company in adjacent areas that are not new to us either.”

“So it would be more obvious for me to imagine that we will be making more deals in areas outside of the core than in the core.”

Doustdar’s comments follow the company’s announcement of plans to launch over five “multi-blockbuster” drugs by 2030, anticipated to generate over $23 billion in sales by 2035.

The company also projected revenue growth comparable to industry peers like Eli Lilly, AstraZeneca and Merck.

Novo Nordisk shares have declined 34% over the past year.

By CEO NA Editorial Staff

Related Posts

Google selects Bezos’ Blue Origin for AI space project
News

Google selects Bezos’ Blue Origin for AI space project

Anthropic sets $1 trillion IPO valuation target
News

Anthropic raises more than $81 billion in record IPO

Walmart beats predictions in latest quarter
News

Walmart raises outlook, anticipating a busy holiday season

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

Disney’s full year earnings prove streaming is successful
News

Disney beats earnings expectations as park attendance grows

Home Depot CFO delivers strategic update as company offers cautious forecast
News

Home Depot names Richard McPhail CEO amid leadership reshuffle

Nvidia due in Supreme Court today
News

Nvidia stock falls as execs push for Huang’s return

No Result
View All Result

Recent Posts

  • New ‘Toxic Hall of Shame’ includes Publix, Trader Joe’s and McDonald’s
  • Google selects Bezos’ Blue Origin for AI space project
  • Anthropic raises more than $81 billion in record IPO
  • Walmart raises outlook, anticipating a busy holiday season
  • AI Has Entered the Boardroom. Who’s Overseeing It?

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.